ACADIA PHARMACEUTICALS INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ACAD in the last 30 days.
See all $ACAD insider activity →Needham reaffirmed its Buy rating on Acadia Pharmaceuticals with a $35 price target, suggesting an 83.1% upside from the Oct 16 close of $19.12. The firm cited Acadia's strong product portfolio and promising pipeline in neurological and rare diseases.
Argus lowered its target price for ACADIA Pharmaceuticals (ACAD) to $18.00. The company focuses on developing and commercializing medicines for CNS disorders and rare diseases.
UBS downgraded Acadia Pharmaceuticals (ACAD) from Buy to Neutral, lowering its price target from $49.00 to $23.00. The company's stock is currently trading at $18.62, with a GF Value™ of $25.90, suggesting it is 28.1% undervalued. Insider sales totaled $1,019,973 over the past three months, and the company has a GF Score™ of 79/100.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ACAD (ACADIA PHARMACEUTICALS INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ACAD coverage spans financial news, market movers and technology.
Analyst upgrade with a higher price target may drive buying interest.
Target price cut suggests expected weaker performance.
The downgrade signals reduced growth expectations and may trigger selling pressure.
Strong upside potential may attract speculative buying in ACAD.
Shares likely to rise as the legal risk is removed.
AlphAI scores every news story that mentions ACAD with an AI model for sentiment and relevance, and aggregates insider trades from ACADIA PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Needham reaffirmed its Buy rating on Acadia Pharmaceuticals with a $35 price target, suggesting an 83.1% upside from the Oct 16 close of $19.12. The firm cited Acadia's strong product portfolio and promising pipeline in neurological and rare diseases.
1 min readArgus lowered its target price for ACADIA Pharmaceuticals (ACAD) to $18.00. The company focuses on developing and commercializing medicines for CNS disorders and rare diseases.
1 min readUBS downgraded Acadia Pharmaceuticals (ACAD) from Buy to Neutral, lowering its price target from $49.00 to $23.00. The company's stock is currently trading at $18.62, with a GF Value™ of $25.90, suggesting it is 28.1% undervalued. Insider sales totaled $1,019,973 over the past three months, and the company has a GF Score™ of 79/100.
2 min readBMO Capital analysts maintained Buy ratings on Pfizer (PFE), ACADIA Pharmaceuticals (ACAD), and Insmed (INSM), with price targets of $35.00, $34.00, and $192.00 respectively. Current share prices are $28.40, $19.56, and $99.39. Analyst consensus for these stocks is Moderate Buy for PFE and ACAD, and Strong Buy for INSM, with average price targets of $29.62, $33.29, and $197.84 respectively.
2 min readRBC reports that the patent dispute between Acadia Pharmaceuticals (ACAD) and Zydus over Nuplazid seems resolved. ACAD shares rose in afternoon trading on Monday, according to RBC's findings on Friday.
1 min readRBC Capital maintained its Outperform rating on Acadia Pharmaceuticals (NASDAQ:ACAD) with a $37.00 price target, citing attractive valuation and reduced risk around Nuplazid revenue. The stock trades at $20.08 with a P/E ratio of 9.09 and PEG ratio of 0.14. Analysts revised earnings upwards, but recent Phase 2 trial results missed primary endpoint, leading to adjusted price targets.
2 min readACADIA Pharmaceuticals (ACAD) rose 0.6% to $20.07, near its 52-week low. RBC Capital reiterated its Outperform rating and $37 price target, citing an undervalued commercial franchise and recent patent developments. The stock had fallen sharply after its experimental drug remlifanserin missed a trial endpoint. A securities law firm is investigating the company's disclosures. The broader market is also supporting biotech stocks.
1 min readAnalysts showed selective bullishness on Sept 25, 2026, with positive calls in tech, healthcare, and industrials. 3M (MMM) was upgraded to Market Perform with a $171 target. ACADIA (ACAD) saw multiple target cuts. Akamai (AKAM) received several target raises. Apple (AAPL) kept Outperform. Chevron (CVX) target raised to $250. Costco (COST) had mixed ratings.
3 min readH.C. Wainwright lowered its price target on Acadia Pharmaceuticals (ACAD) to $33 from $37, citing a Phase 2 trial miss. The stock fell 22% to $20.68. Despite this, some analysts see value, with price targets up to $49. The trial missed its primary endpoint but hit a key secondary endpoint.
2 min readACADIA PHARMACEUTICALS INC (ACAD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) — Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 develop
2 min read
